Brief: Nanobiotix Announces New Results From A Phase 1 Study Evaluating JNJ-1900 (Nbtxr3)
17/09/2025 21:33
Sept 17 (Reuters) - Nanobiotix SA NANOB.PA: NANOBIOTIX ANNOUNCES NEW RESULTS FROM A PHASE 1 STUDY EVALUATING JNJ-1900 (NBTXR3) IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS AS A 2L+ THERAPY FOR PATIENTS WITH PRIMARY CUTANEOUS MELANOMA RESISTANT TO ANTI-PD-1 NANOBIOTIX SA - DATA SHOW FAVORABLE SAFETY PROFILE AND EARLY EFFICACY SIGNALS NANOBIOTIX SA - PHASE 2 DOSE ESTABLISHED AT 33% OF GROSS TUMOR VOLUME NANOBIOTIX SA - 47.4% OBJECTIVE RESPONSE RATE OBSERVED IN ALL LESIONS Source text: ID:nGNX8Ng7fc Further company coverage: NANOB.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering